Oak Grove Capital’s Sarepta Therapeutics SRPT Stock Holding History

Oak Grove Capital’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-925	Closed	-$149K	–	142
2018 Q3	$149K	Hold	925	–	–	0.13%	55
2018 Q2	$122K	Hold	925	–	–	0.12%	52
2018 Q1	$69K	Buy	+925	New	+$61.7K	0.08%	63

Other funds holding SRPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Oak Grove Capital's SRPT Position: Q4 2018 in Review

Oak Grove Capital sold out of Sarepta Therapeutics (SRPT) in Q4 2018, closing a stake of 925 shares — an estimated $149K sold.

Oak Grove Capital first reported a position in SRPT in Q1 2018 and held it in 3 quarters. The position peaked at $149K in Q3 2018. 336 funds tracked by Wall St. Rank hold SRPT as of Q4 2018.

Oak Grove Capital reported no remaining Sarepta Therapeutics position as of Q4 2018 after selling out during the quarter.
Oak Grove Capital sold 925 Sarepta Therapeutics shares in Q4 2018, an estimated $149K.
Oak Grove Capital first reported a position in Sarepta Therapeutics in Q1 2018 and held it in 3 quarters.
Oak Grove Capital's Sarepta Therapeutics position peaked at $149K in Q3 2018.
336 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2018.

Based on Oak Grove Capital's 13F filing for Q4 2018, filed 15 Feb 2019.